OPTN vs. RNAC, IMUX, FGEN, CTMX, ELYM, MCRB, RZLT, CLSD, SCTL, and BRNS
Should you be buying OptiNose stock or one of its competitors? The main competitors of OptiNose include Cartesian Therapeutics (RNAC), Immunic (IMUX), FibroGen (FGEN), CytomX Therapeutics (CTMX), Eliem Therapeutics (ELYM), Seres Therapeutics (MCRB), Rezolute (RZLT), Clearside Biomedical (CLSD), Societal CDMO (SCTL), and Barinthus Biotherapeutics (BRNS). These companies are all part of the "pharmaceutical preparations" industry.
Cartesian Therapeutics (NASDAQ:RNAC) and OptiNose (NASDAQ:OPTN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation, community ranking and dividends.
87.0% of Cartesian Therapeutics shares are owned by institutional investors. Comparatively, 85.6% of OptiNose shares are owned by institutional investors. 31.2% of Cartesian Therapeutics shares are owned by company insiders. Comparatively, 2.2% of OptiNose shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Cartesian Therapeutics has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500. Comparatively, OptiNose has a beta of -0.24, suggesting that its share price is 124% less volatile than the S&P 500.
Cartesian Therapeutics presently has a consensus target price of $45.00, suggesting a potential upside of 117.18%. OptiNose has a consensus target price of $4.00, suggesting a potential upside of 332.29%. Given Cartesian Therapeutics' higher probable upside, analysts clearly believe OptiNose is more favorable than Cartesian Therapeutics.
In the previous week, Cartesian Therapeutics had 12 more articles in the media than OptiNose. MarketBeat recorded 12 mentions for Cartesian Therapeutics and 0 mentions for OptiNose. OptiNose's average media sentiment score of 0.77 beat Cartesian Therapeutics' score of 0.00 indicating that Cartesian Therapeutics is being referred to more favorably in the media.
OptiNose has a net margin of -50.06% compared to OptiNose's net margin of -845.01%. Cartesian Therapeutics' return on equity of 0.00% beat OptiNose's return on equity.
OptiNose has higher revenue and earnings than Cartesian Therapeutics.
OptiNose received 236 more outperform votes than Cartesian Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Cartesian Therapeutics an outperform vote while only 63.02% of users gave OptiNose an outperform vote.
Summary
Cartesian Therapeutics beats OptiNose on 9 of the 15 factors compared between the two stocks.
Get OptiNose News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPTN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OPTN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OptiNose Competitors List
Related Companies and Tools
